Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Ionis Pharmaceuticals Inc โปรไฟล์



สัญลักษณ์ย่อของหุ้นIONS

ชื่อบริษัทIonis Pharmaceuticals Inc

วันที่เสนอขายครั้งแรกMay 17, 1991

ซีอีโอMonia (Brett P)

จำนวนพนักงาน1069

ประเภทการรักษาความปลอดภัยOrdinary Share

สิ้นปีงบประมาณMay 17

ที่อยู่2855 Gazelle Court

เมืองCARLSBAD

ตลาดหลักทรัพย์NASDAQ OMX - NASDAQ BASIC

ประเทศUnited States of America

รหัสไปรษณีย์92010

โทรศัพท์17609319200

เว็บไซต์https://www.ionis.com/

สัญลักษณ์ย่อของหุ้นIONS

วันที่เสนอขายครั้งแรกMay 17, 1991

ซีอีโอMonia (Brett P)

ผู้บริหารบริษัทของ Ionis Pharmaceuticals Inc



ชื่อ

ชื่อ/ตำแหน่ง

ตำแหน่ง

การถือหุ้น

เปลี่ยน

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

242.76K

+0.04%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

161.30K

+3.24%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

82.66K

-60.76%

Mr. Brian Birchler

Executive Vice President - Corporate and Development Operations

67.56K

+0.09%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

59.86K

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

59.66K

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

59.20K

+0.11%

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Chairman of the Board

36.33K

Mr. Kyle Jenne

Executive Vice President, Chief Global Product Strategy Officer

23.71K

+30.89%

Dr. Eric E. Swayze, Ph.D.

Executive Vice President - Research

22.08K

-48.02%

ดูเพิ่มเติม